A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis
- PMID: 11886356
- DOI: 10.1034/j.1600-0404.2002.1o369.x
A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis
Abstract
Objective: To investigate the efficacy of two different high doses of intravenous methylprednisolone (IVMP) during Multiple Sclerosis (MS) relapses.
Background: Transcranial Magnetic Stimulation (TMS) is the most sensitive neurophysiological ascertainment to quantify motor disability, to follow the recovery from an MS relapse, and to detect the response to treatment.
Design and method: Twenty-four clinically definite relapsing - remitting MS patients presenting a relapse were randomly assigned to a treatment for 5 days with IVMP 1 or 2 g/day. The response to treatment of each patient was evaluated through Expanded Disability Status Scale (EDSS), Medical Research Council (MRC) score, and TMS by means of motor evoked potential (MEP) parameters.
Results: Motor threshold (MT), central motor conduction time (CMCT) and MRC showed a higher improvement with the highest dose of IVMP. Silent period and EDSS improved with both treatments.
Conclusion: The dose of 2 g/day of IVMP is more effective in MS relapse.
Similar articles
-
Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.Mult Scler. 2016 Jan;22(1):117-21. doi: 10.1177/1352458515590648. Epub 2015 Jun 25. Mult Scler. 2016. PMID: 26540732 Clinical Trial.
-
Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.Mult Scler. 2004 Aug;10(4):413-6. doi: 10.1191/1352458504ms1068oa. Mult Scler. 2004. PMID: 15327039
-
A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.Mult Scler. 2004 Feb;10(1):89-91. doi: 10.1191/1352458504ms978sr. Mult Scler. 2004. PMID: 14760960 Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.Neurodegener Dis Manag. 2021 Apr;11(2):177-185. doi: 10.2217/nmt-2020-0051. Epub 2021 Mar 11. Neurodegener Dis Manag. 2021. PMID: 33703936
Cited by
-
Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities.J Neurol. 2007 Feb;254(2):220-7. doi: 10.1007/s00415-006-0334-5. Epub 2007 Feb 17. J Neurol. 2007. PMID: 17308868
-
Monitoring of the pharmacological treatment availability in patients with multiple sclerosis in the Greater Poland population.Reumatologia. 2023;61(6):473-480. doi: 10.5114/reum/177143. Epub 2024 Jan 18. Reumatologia. 2023. PMID: 38322107 Free PMC article. Review.
-
Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee.Clin Neurophysiol. 2023 Jun;150:131-175. doi: 10.1016/j.clinph.2023.03.010. Epub 2023 Mar 29. Clin Neurophysiol. 2023. PMID: 37068329 Free PMC article. Review.
-
Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials.Degener Neurol Neuromuscul Dis. 2019 Jul 1;9:55-78. doi: 10.2147/DNND.S208815. eCollection 2019. Degener Neurol Neuromuscul Dis. 2019. PMID: 31308790 Free PMC article.
-
Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis.J Neurol. 2009 Jun;256(6):933-8. doi: 10.1007/s00415-009-5047-0. Epub 2009 Mar 1. J Neurol. 2009. PMID: 19252788
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical